Back to top
February
20
2017

Daiichi, ArQule’s struggling tivantinib fails in phase 3 liver cancer test

After fluffing its lines in two mid-to-late stage trials in lung and colorectal cancer over the past few years, Daiichi and ArQule had hoped that tivantinib…

Read More
February
8
2017

Gene therapy helps deaf mice hear sounds as soft as whispers

Scientists at Harvard Medical School are reporting today that they’ve perfected a form of gene therapy originally developed to restore hearing, and as a result,…

Read More
February
7
2017

Biotech leaders take on Trump’s immigration ban

More than 160 biotech and VC execs have signed a strongly worded letter in Nature Biotech today denouncing President Donald Trump’s recent three-month immigration executive…

Read More
February
1
2017

PhRMA Board of Directors Elects New Officers

The Pharmaceutical Research and Manufacturers of America (PhRMA) board of directors elected new officers and welcomed a new member company today. Joaquin Duato, worldwide chairman,…

Read More
January
19
2017

Rebooted Merrimack names Sanofi Genzyme SVP as CEO

Merrimack Pharmaceuticals has lured Dr. Richard Peters from Sanofi Genzyme to serve as its CEO. Peters will take charge of a rebooted, slimmed-down organization that…

Read More
January
19
2017

Lilly buys migraine biotech CoLucid, and the drug it outlicensed, for $960M

Eli Lilly says it will spend nearly $1 billion to buy out CoLucid Pharmaceuticals and get its hands on its late-stage acute migraine candidate, which Lilly…

Read More
"Every science begins as philosophy and ends as art." Will Durant,